Home › Funds › Rangeley Capital, LLC › ACET

Rangeley Capital, LLC position in ACET

ADICET BIO INC · Health Care

Rangeley Capital, LLC reported holding 64,000 shares of ACET (ADICET BIO INC) in its Q3 2026 13F filing — a position valued at US$457K, representing 0.63% of its reported portfolio and ranking #50 among its reported holdings. Rangeley Capital, LLC has disclosed ACET holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

Latest position (Q3 2026)64.00K sh
Reported value held$456.96K
Portfolio Weight0.63%
First reportedQ3 2025
Last changeAdd
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How Rangeley Capital, LLC's ACET position evolved

Rangeley Capital, LLC first disclosed a stake in ACET in Q3 2025 at 75,000 shares (US$61K). The position peaked in Q3 2026 at 64,000 shares, worth US$457K. Across 5 filings, Rangeley Capital, LLC increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 64,000 shares valued at US$457K — an increase of 13,108 shares quarter over quarter.. Notable position changes include a 67% trim in Q4 2025 (shares fell 19% over the following quarter), a 124% increase in Q1 2026 (shares rose 27% over the following quarter), a 26% increase in Q3 2026 (shares fell 61% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2025 75.00K $60.77K New
Q4 2025 25.00K $210.51K Reduce
Q1 2026 56.00K $381.36K Add
Q2 2026 50.89K $439.71K Reduce
Q3 2026 64.00K $456.96K Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ACET and 13F data

ACET (ADICET BIO INC) is a Health Care company. 24 other funds we track also report a position in ACET — the largest reported positions include Stonepine Capital Management, LLC (US$1.3M), Carlyle Group Inc. (US$1.3M), REGENERON PHARMACEUTICALS, INC. (US$432K). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ACET

All ACET fund holders →

FAQ

How long has Rangeley Capital, LLC held ACET?

Rangeley Capital, LLC has disclosed ACET holdings in 5 of the last 5 reported quarters, going back to Q3 2025.

What is Rangeley Capital, LLC's current position in ACET?

As of Q3 2026, Rangeley Capital, LLC holds 64.00K shares of ACET (ADICET BIO INC), valued at $456.96K, representing 0.63% of its reported portfolio and ranking #50.

Has Rangeley Capital, LLC been buying or selling ACET?

In the latest 13F filing (Q3 2026), Rangeley Capital, LLC increased its position in ACET. The position peaked in Q3 2026 at 64.00K shares.

Which other funds hold ACET?

Other major institutional holders of ACET include Stonepine Capital Management, LLC, Carlyle Group Inc., REGENERON PHARMACEUTICALS, INC., among 24 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.